28,360 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by WINTON GROUP Ltd

WINTON GROUP Ltd acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 28,360 shares of the medical research company’s stock, valued at approximately $14,219,000.

Several other hedge funds have also modified their holdings of TMO. California State Teachers Retirement System grew its holdings in Thermo Fisher Scientific by 49,331.5% during the second quarter. California State Teachers Retirement System now owns 282,654,735 shares of the medical research company’s stock worth $141,711,778,000 after acquiring an additional 282,082,924 shares during the period. J. Stern & Co. LLP boosted its position in shares of Thermo Fisher Scientific by 58,006.4% during the 4th quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock worth $18,258,082,000 after purchasing an additional 31,455,105 shares in the last quarter. BlackRock Inc. acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth $15,501,867,000. Corient Private Wealth LP acquired a new stake in shares of Thermo Fisher Scientific in the second quarter valued at about $382,547,000. Finally, Norges Bank purchased a new stake in Thermo Fisher Scientific during the fourth quarter worth about $3,072,744,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Up 0.7%

Shares of NYSE:TMO opened at $607.23 on Thursday. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The company has a market capitalization of $224.52 billion, a P/E ratio of 32.66, a P/E/G ratio of 2.52 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $647.00. The stock’s fifty day simple moving average is $577.00 and its 200-day simple moving average is $517.24.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. The firm had revenue of $11.99 billion during the quarter, compared to analysts’ expectations of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm’s quarterly revenue was up 10.5% compared to the same quarter last year. During the same quarter last year, the business posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s payout ratio is currently 10.11%.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on TMO. Scotiabank started coverage on shares of Thermo Fisher Scientific in a research report on Wednesday. They set an “outperform” rating for the company. BMO Capital Markets cut Thermo Fisher Scientific to a “market perform” rating in a report on Wednesday. Sanford C. Bernstein began coverage on Thermo Fisher Scientific in a research report on Friday, June 26th. They set a “market perform” rating and a $520.00 target price on the stock. Wolfe Research began coverage on Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 price target for the company. Finally, Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, five have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $624.64.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, EVP Michael Shafer sold 25,500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total value of $15,300,000.00. Following the sale, the executive vice president directly owned 20,994 shares of the company’s stock, valued at approximately $12,596,400. This trade represents a 54.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa Britt sold 11,440 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the completion of the transaction, the vice president owned 14,784 shares in the company, valued at approximately $9,064,366.08. This trade represents a 43.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 73,768 shares of company stock worth $44,122,820. 0.33% of the stock is currently owned by insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global supplier of scientific equipment, laboratory services and analytical technologies. The company serves pharmaceutical and biotechnology companies, clinical laboratories, academic and government institutions, industrial businesses and other research organizations.

Its products and services include laboratory instruments, analytical systems, reagents, consumables, software and related services. Thermo Fisher also provides laboratory supplies and equipment, bioproduction solutions, genetic analysis technologies, clinical diagnostics, specialty diagnostic products and contract research and manufacturing services through its laboratory services businesses.

The company was formed in 2006 through the merger of Thermo Electron Corporation and Fisher Scientific International.